Zepbound Side Effects: Complete FDA Safety Guide
Zepbound (tirzepatide) is FDA-approved for chronic weight management. The most common side effects are gastrointestinal, nausea, diarrhoea, vomiting, constipation, abdominal pain, and the most serious are pancreatitis, gallbladder disease, kidney injury, and a boxed warning about thyroid C-cell tumours. Oral contraceptives may be less effective at Zepbound doses.
Zepbound (Tirzepatide) is approved as a Dual GIP/GLP-1 receptor agonist. Most common side effects are gastrointestinal (nausea, vomiting, diarrhoea, constipation). Serious risks include pancreatitis, kidney injury, gallbladder disease and hypoglycaemia with insulin. It carries an FDA boxed warning for thyroid C-cell tumours.
Key Takeaways
- Zepbound carries a boxed warning for thyroid C-cell tumours, contraindicated if personal or family history of medullary thyroid carcinoma or MEN2.
- Most common side effects: nausea, diarrhoea, vomiting, constipation, abdominal pain, usually worst at dose initiation and escalation.
- Major label warnings: pancreatitis, gallbladder disease, acute kidney injury, hypersensitivity reactions, suicidal behaviour and ideation (monitor mood).
- Zepbound may reduce the effectiveness of oral contraceptives, use a non-oral contraceptive method or add a barrier for 4 weeks after initiation and each dose escalation.
- Alcohol compounds nausea, dehydration, and gallbladder/pancreatitis risks during rapid weight loss.
- Disclose Zepbound use before any procedure due to delayed gastric emptying and aspiration risk.
What is Zepbound, and what is it used for?
Zepbound is tirzepatide approved for chronic weight management. It is the same molecule as Mounjaro but dosed and indicated for weight loss.
| Property | Detail |
|---|---|
| Generic name | Tirzepatide |
| Brand names | Zepbound (weight management), Mounjaro (T2D) |
| Drug class | Dual GIP / GLP-1 receptor agonist |
| FDA approval status | Approved, chronic weight management |
| Route | Subcutaneous injection, once weekly |
| Boxed warning | Thyroid C-cell tumours (animal data) |
| Common GI side effects | Nausea, diarrhoea, vomiting, constipation, abdominal pain |
| Contraceptive caution | Reduced oral contraceptive efficacy, barrier method recommended for 4 weeks after each dose change |
What are the side effects of Zepbound?
The FDA prescribing information for Zepbound groups side effects into common gastrointestinal symptoms (very frequent at initiation and dose escalation) and serious warnings (less frequent but clinically important). The table below summarises the labelled categories with severity colour-coding.
| Side Effect Category | What May Occur | Why It Matters |
|---|---|---|
| Pancreatitis | Severe, persistent abdominal pain (sometimes radiating to the back), nausea, vomiting | All GLP-1 labels warn about acute pancreatitis. Stop the medicine and seek urgent assessment. |
| Thyroid C-cell tumours (boxed warning) | Neck mass, hoarseness, difficulty swallowing, persistent neck pain | Animal studies show medullary thyroid carcinoma risk. Contraindicated if personal or family history of MTC or MEN2. |
| Acute kidney injury | Reduced urine output, swelling, fatigue, usually after vomiting or diarrhoea | Dehydration from GI side effects can precipitate AKI, particularly in patients with prior renal disease. |
| Severe hypoglycaemia | Sweating, shakiness, confusion, palpitations, seizure, loss of consciousness | Risk rises sharply when combined with insulin or sulfonylureas. Dose reduction of the other glucose-lowering drug is usually required. |
| Gallbladder disease | Right-upper abdominal pain, fever, jaundice | Cholelithiasis and cholecystitis are reported, especially with rapid weight loss. |
| Severe gastrointestinal reactions | Persistent nausea, vomiting, diarrhoea, constipation, abdominal pain | Common and dose-dependent. Most pronounced during initiation and dose escalation. |
| Diabetic retinopathy worsening | Blurred vision, vision changes | Rapid glucose lowering has been associated with transient worsening, relevant in long-standing type 2 diabetes. |
| Hypersensitivity reactions | Rash, urticaria, angioedema, anaphylaxis | Stop the medicine and seek urgent care for serious allergic features. |
| Injection-site reactions | Redness, swelling, itching, induration at the injection site | Usually mild; persistent reactions warrant clinical review. |
| Aspiration risk during anaesthesia | Delayed gastric emptying may leave food in the stomach during sedation | Disclose GLP-1 use to your anaesthetist before any procedure or surgery. |
Taking Zepbound alongside other medications?
Check Zepbound against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
How does Zepbound work, and why does that drive the side effects?
Tirzepatide activates both GIP and GLP-1 receptors, producing potent appetite suppression and slowed gastric emptying. At the higher doses used for weight loss, GI side effects and the contraceptive-absorption caution are more prominent than at diabetes-only doses.
Can you drink alcohol while taking Zepbound?
Alcohol is not contraindicated, but adds calories that work against weight goals and worsens GI symptoms during dose escalation.
Symptoms and when to seek care
Seek urgent medical assessment if you experience any of the following while taking Zepbound:
- Severe, persistent abdominal pain (possible pancreatitis)
- Sudden swelling of the face, lips, tongue or throat, or difficulty breathing (allergic reaction)
- Right-upper abdominal pain with fever or jaundice (gallbladder disease)
- Severe vomiting or diarrhoea with reduced urine output (dehydration / kidney injury)
- Severe hypoglycaemia, sweating, confusion, palpitations, loss of consciousness (especially if also on insulin or sulfonylurea)
- New neck mass, hoarseness, or difficulty swallowing (thyroid concern)
- New or worsening depression, mood changes, or suicidal thoughts (Wegovy/Zepbound)
Common Questions About Zepbound Side Effects
Nausea, diarrhoea, vomiting, constipation, abdominal pain, fatigue, injection-site reactions, hair loss, and gastroenteritis. Most GI symptoms are mild to moderate and improve with continued use.
Yes. Zepbound can reduce the effectiveness of oral contraceptives. Use a non-oral method (IUD, implant, injection) or add a barrier method for 4 weeks after starting Zepbound and after each dose increase.
Both contain tirzepatide. Zepbound is dosed and indicated for chronic weight management; Mounjaro is for type 2 diabetes. The molecule is identical.
Thyroid C-cell tumours, based on rodent studies. Zepbound is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).
Discuss with your prescriber and anaesthetist. GLP-1 medicines slow gastric emptying, which can leave residual food in the stomach during sedation and increase aspiration risk. Many anaesthetic services now pause GLP-1 medicines before elective procedures.
References
- U.S. Food & Drug Administration. Ozempic (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Wegovy (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Mounjaro (tirzepatide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Zepbound (tirzepatide) prescribing information. fda.gov.
- European Medicines Agency. Ozempic, Wegovy, Mounjaro, EPAR product information. ema.europa.eu.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Check Zepbound against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.